Abstract
Meningiomas are the most common primary intracranial tumors in adults comprising about one-third of cases. Most of them are slow-growing and follow a benign course. However, some may behave aggressively with recurrence and even metastasis. Histopathological features have long been regarded as the gold standard for diagnosis, grading, and prognostication. Advances in genomics and molecular characteristics of meningiomas have uncovered the potential use of many biomarkers for more accurate grading and prediction of prognosis and recurrence. Precision clinical trials are needed to utilize these biomarkers for targeted therapy. The present review is a snapshot of some of these important updates in meningioma as per the 2021 WHO Classification of Tumors of the Central Nervous System (WHO CNS5).
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
